Wolfgang Miesbach: The Growing Impact of Age-Related Disease in Hemophilia
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared post on LinkedIn:
“Crucial real-world data on our aging haemophilia population!
As life expectancy improves, our patients face new clinical challenges.
A massive Emory University analysis of US Medicare claims (2000-2020) looking at 2,058 adults (avg age 57.2; 1,735 Hem A or 323 Hem B) reveals critical shifts:
- Surging Comorbidities: Rates of arthropathy (the highest burden by far), liver disease, CVD, and renal disease are substantially higher in haemophilia patients vs. the matched US population.
- Elevated Mortality: Males with haemophilia face a 12% higher mortality rate (aHR is equal to 1.12) vs. the general public. (No significant difference in females: aHR is equal to 0.96).
- The Multiplier Effect: Having common chronic diseases (Cancer, COPD, CHF, CVD, Diabetes) drives a massive 67–300% increase in mortality rates for these patients.
We are managing the first true cohort of aging haemophilia patients. This data screams for a shift toward proactive, multidisciplinary prevention to tackle age-related chronic diseases alongside core bleeding risks.
Kudos to Stacey Fedewa, Christine Kempton, MD, MSc, and the Emory, Hemophilia of Georgia team for this excellent work!”

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis